Scarica l'app Stockscreener
1.20
4.00%
-0.05
Precedente Chiudi:
$1.25
Aprire:
$1.22
Volume 24 ore:
68,400
Relative Volume:
0.61
Capitalizzazione di mercato:
$6.67M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.23%
1M Prestazione:
-31.82%
6M Prestazione:
-73.39%
1 anno Prestazione:
-92.65%
Intervallo 1D:
$1.18
$1.27
Intervallo di 1 settimana:
$0.97
$1.53
Portata 52W:
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Nome
Traws Pharma Inc
Settore
Industria
Telefono
267-759-3680
Indirizzo
12 PENNS TRAIL, NEWTOWN
Confronta TRAW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.20 | 6.61M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-18 | Iniziato | Guggenheim | Buy |
| 2018-03-01 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-17 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-09 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-27 | Iniziato | Laidlaw | Buy |
| 2015-07-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Traws Pharma Inc Borsa (TRAW) Ultime notizie
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MSN
Traws Pharma Unveils New Strategic Antiviral Focus - TipRanks
Traws Pharma’s Q1 2025 Results Highlight Progress and Profit - TipRanks
Traws Pharma Reports First Quarter 2025 Results And Business Highlights - marketscreener.com
Traws Pharma Reports Q1 2025 Financial Results - TipRanks
Traws Pharma Reports First Quarter 2025 Results and Business Highlights - GlobeNewswire
Traws Pharma Earnings Surge to $21.5M as Former CDC Director Backs Novel Flu and COVID Drug Pipeline - Stock Titan
Renaissance Technologies LLC Takes $89,000 Position in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
Geode Capital Management LLC Makes New $185,000 Investment in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
TRAW stock touches 52-week low at $1.51 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $1.51 amid sharp annual decline - Investing.com India
Traws Pharma Appoints New Chairman Amid Leadership Changes - MSN
Traws Pharma appoints new interim CEO with compensation details By Investing.com - Investing.com Canada
Traws Pharma appoints new interim CEO with compensation details - Investing.com Australia
Traws Pharma announces $50 million stock offering potential - Investing.com Australia
Traws Pharma announces $50 million stock offering potential By Investing.com - Investing.com Canada
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs - MSN
TRAW stock touches 52-week low at $2.01 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $2.01 amid sharp annual decline - Investing.com India
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports 2024 Results and Strategic Progress - TipRanks
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference - MSN
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost - Investing.com
Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19 - MSN
Traws Pharma Reports 2024 Financial Results and CEO Change - TipRanks
Traws Pharma Reports Full Year 2024 Results and Business Highlights - GlobeNewswire
Traws Pharma's Bird Flu Drug Shows Promise Despite $166M Annual LossKey Updates - Stock Titan
Traws Pharma (TRAW) Expected to Announce Quarterly Earnings on Monday - Defense World
Traws Pharma Announces CEO Transition as Werner Cautreels Retires - MSN
Traws Pharma announces CEO retirement and interim successor By Investing.com - Investing.com South Africa
Traws Pharma announces CEO retirement and interim successor - Investing.com India
Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis - MarketScreener
Traws Pharma Announces Management Updates - GlobeNewswire
Leadership Shift at Traws Pharma: Chairman Steps Up as CEO Exits, Key Antiviral Programs Continue - Stock Titan
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment - MSN
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - The Manila Times
Traws Pharma to Host Investor Event on Bird Flu and COVID - GlobeNewswire
Former CDC Director Unveils Game-Changing Bird Flu and COVID Treatments at Traws Pharma Event - Stock Titan
Traws Pharma Inc Azioni (TRAW) Dati Finanziari
Non sono disponibili dati finanziari per Traws Pharma Inc (TRAW). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.52%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):